Drug Profile
Research programme: chemokine receptor monoclonal antibodies - Sorrento Therapeutics
Alternative Names: anti-CCR2 mAbs - Sorrento Therapeutics; anti-CCR6 mAbs - Sorrento Therapeutics; anti-CXCR3 mAbs - Sorrento Therapeutics; anti-CXRC5 mAbs - Sorrento Therapeutics; STI-A120X; STI-B0201; STI-B020X; STI-B0211; STI-B0221; STI-B0234; STI-B030X; STI-B100XLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action CCR2 receptor antagonists; CCR6 receptor antagonists; CXCR3 receptor antagonists; CXCR5 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Parenteral)
- 04 Jul 2013 Preclinical trials in Multiple sclerosis in USA (Parenteral)